Advertisement
Advertisement

AKBA

AKBA logo

Akebia Therapeutics, Inc.

1.04
USD
Sponsored
-0.02
-1.42%
Jun 25, 12:22 UTC -4
Open

AKBA Earnings Reports

Positive Surprise Ratio

AKBA beat 18 of 42 last estimates.

43%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$51.96M
/
-$0.04
Implied change from Q1 26 (Revenue/ EPS)
-2.96%
/
+33.33%
Implied change from Q2 25 (Revenue/ EPS)
-16.83%
/
--

Akebia Therapeutics, Inc. earnings per share and revenue

On May 07, 2026, AKBA reported earnings of -0.03 USD per share (EPS) for Q1 26, missing the estimate of -0.02 USD, resulting in a -4.90% surprise. Revenue reached 53.54 million, compared to an expected 52.70 million, with a 1.60% difference. The market reacted with a -20.27% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 51.96 million USD, implying an increase of 33.33% EPS, and decrease of -2.96% in Revenue from the last quarter.
FAQ
For Q1 2026, Akebia Therapeutics, Inc. reported EPS of -$0.03, missing estimates by -4.9%, and revenue of $53.54M, 1.6% above expectations.
The stock price moved down -20.27%, changed from $1.48 before the earnings release to $1.18 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 6 analysts, Akebia Therapeutics, Inc. is expected to report EPS of -$0.04 and revenue of $51.96M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement